Nothing Special   »   [go: up one dir, main page]

MX2022007955A - Regimenes de dosificacion de erdafitinib. - Google Patents

Regimenes de dosificacion de erdafitinib.

Info

Publication number
MX2022007955A
MX2022007955A MX2022007955A MX2022007955A MX2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A MX 2022007955 A MX2022007955 A MX 2022007955A
Authority
MX
Mexico
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
MX2022007955A
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Jose Perez
Porre Peter Marie Z De
Anjali Narayan Avadhani
Yohann Loriot
Arlene O Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022007955(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022007955A publication Critical patent/MX2022007955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para el tratamiento del cáncer con erdafitinib.
MX2022007955A 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib. MX2022007955A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20

Publications (1)

Publication Number Publication Date
MX2022007955A true MX2022007955A (es) 2022-07-27

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.

Country Status (24)

Country Link
US (2) US11077106B2 (es)
EP (2) EP4286005A3 (es)
JP (2) JP2020505425A (es)
KR (1) KR20190110581A (es)
CN (1) CN110198716A (es)
AU (2) AU2018216969B2 (es)
BR (1) BR112019016043A2 (es)
CA (1) CA3049737A1 (es)
DK (1) DK3576740T3 (es)
ES (1) ES2953005T3 (es)
FI (1) FI3576740T3 (es)
HR (1) HRP20230697T1 (es)
HU (1) HUE062453T2 (es)
IL (1) IL268463A (es)
JO (1) JOP20190190A1 (es)
LT (1) LT3576740T (es)
MX (2) MX2019009304A (es)
PH (1) PH12019501885A1 (es)
PL (1) PL3576740T3 (es)
RS (1) RS64778B1 (es)
SG (2) SG10202105110VA (es)
SI (1) SI3576740T1 (es)
TW (1) TW202402290A (es)
UA (1) UA126336C2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6766037B2 (ja) 2014-09-26 2020-10-07 ヤンセン ファーマシューティカ エヌ．ベー． Ｆｇｆｒ阻害剤による治療に応答性であるがん患者を同定する際の、ｆｇｆｒ変異遺伝子パネルの使用
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA55522A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
HUE062453T2 (hu) 2023-11-28
RS64778B1 (sr) 2023-11-30
AU2018216969A1 (en) 2019-07-25
EP3576740A1 (en) 2019-12-11
SG10202105110VA (en) 2021-06-29
BR112019016043A2 (pt) 2020-03-31
EP4286005A2 (en) 2023-12-06
FI3576740T3 (fi) 2023-08-31
AU2024201871A1 (en) 2024-04-11
CN110198716A (zh) 2019-09-03
EP3576740B1 (en) 2023-06-14
TW202402290A (zh) 2024-01-16
MX2019009304A (es) 2019-09-19
PL3576740T3 (pl) 2023-09-11
LT3576740T (lt) 2023-08-10
HRP20230697T1 (hr) 2023-10-13
SI3576740T1 (sl) 2023-10-30
UA126336C2 (uk) 2022-09-21
ES2953005T3 (es) 2023-11-07
AU2018216969B2 (en) 2024-04-11
EP4286005A3 (en) 2024-03-06
CA3049737A1 (en) 2018-08-09
US11077106B2 (en) 2021-08-03
SG11201907199QA (en) 2019-09-27
IL268463A (en) 2019-09-26
PH12019501885A1 (en) 2020-06-29
JP2020505425A (ja) 2020-02-20
US20220110935A1 (en) 2022-04-14
DK3576740T3 (da) 2023-07-24
JOP20190190A1 (ar) 2019-08-04
US20200022976A1 (en) 2020-01-23
JP2023022190A (ja) 2023-02-14
KR20190110581A (ko) 2019-09-30

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3641770A4 (en) METHOD OF TREATMENT OF CANCER
PH12017501999A1 (en) K-ras modulators
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
WO2018136617A3 (en) Bacteria for treating cancer
MX2020003770A (es) Terapias de combinacion para tratar cancer.
EA201991818A1 (ru) Лечение рака
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2020006297A (es) Variantes de cd19.
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2020007742A (es) Procesos para preparar fluorocetolidos.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2018000694A (es) Tratamiento del prurito.
MX2021009670A (es) Tratamiento para el cancer.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.